Anirban Maitra, Laura and Isaac Perlmutter Professor of Pathology, Director, Perlmutter Cancer Center, shared a post on X:
“From Revolution Medicines data on Zoldonrasib plus Daraxonrasib in 2nd and 3rd line metastatic Pancreatic Cancer – presented at ESMO GI 2026.
Small numbers but even a few years back, who would have imagined survival curves like this in 2nd and 3rd line metastatic Pancreatic cancer? Amazing!”
Other articles featuring Anirban Maitra on OncoDaily.